Form 144 TG THERAPEUTICS, INC. Filed by: Charney Laurence N

Thu, 10 Sep 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260910/27049137.html

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

AUSTIN, Texas, Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Today's multiple sclerosis treatments can slow down disease progression, but none of them halt it outright, and none give back the function patients have already lost. Close to a million people in the United States, and nearly 2.9 million worldwide, live with that reality, watching a condition that steadily chips away at mobility, eyesight and basic physical control. That gap in treatment options just picked up a serious new contender. Quantum BioPharma Ltd. (NASDAQ: QNTM) (profile) has

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Thu, 10 Sep 2026 08:30:00 -0400

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:30:00 -0400

NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the H.C. Wainwright 28th Annual Global Investment Conference, being held on September 14 - 16, 2026. The fireside chat is scheduled to take place on Monday, September 14, 2026, at 12:00pm ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Thu, 10 Sep 2026 07:30:00 -0400

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

Fri, 07 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26892026.html

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

Fri, 07 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260807/26892026.html

TG Therapeutics (TGTX) PT Raised to $72 at JPMorgan

Fri, 07 Aug 2026 09:40:09 -0400

JPMorgan analyst Brian Cheng raised the price target on TG Therapeutics (NASDAQ: TGTX) to $72.00 (from $65.00) while maintaining a Overweight rating.

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -

- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -

- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -

- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -

- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Thu, 06 Aug 2026 07:01:00 -0400

- First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% remaining -
- In late-breaking data at EASL, PBGENE-HBV demonstrated sustained pgRNA loss in 100% of evaluable patients; pgRNA is the distinct serum biomarker for cccDNA elimination by PBGENE-HBV -
- Multiple DMD clinical trial sites now actively recruiting for the Phase 1/2 FUNCTION-DMD trial -
- Next PBGENE-HBV and PBGENE-DMD clinical updates targeted for year-end 2026 -
- Cash balance of $112.4 million including cash, cash equivalents and restricted cash as of

StreetInsider.com News Articles

Form 144 TG THERAPEUTICS, INC. Filed by: Charney Laurence N

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

Form 4 TG THERAPEUTICS, INC. For: Aug 06 Filed by: Charney Laurence N

TG Therapeutics (TGTX) PT Raised to $72 at JPMorgan

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update

Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update